Inactive Instrument

Press Releases SEDA MEDI Nasdaq Stockholm

Equities

Sedana Medical completes patient recruitment for its clinical program in the US	05-29	AQ
Report from Sedana Medical's annual general meeting on 22 May 2024	05-22	AQ
Sedana Medical Q1 - Set to beat conservative sales target	04-26	AQ
Sedana Medical AB's Interim report January-March 2024	04-25	AQ
Sedana Medical completes patient recruitment for INSPiRE-ICU 1 clinical trial in the US	04-25	AQ
Notice of Annual General Meeting in Sedana Medical	04-22	AQ
Sedana Medical publishes its Annual Report for 2023	04-15	AQ
Invitation to presentation of Sedana Medical's interim report for the first quarter 2024	04-05	AQ
Sedana Medical Q4 - Likely to beat conservative 2024 sales target	02-16	AQ
Sedana Medical AB's Year-end report 2023	02-15	AQ
Invitation to presentation of Sedana Medical's fourth quarter and year-end report for 2023	01-25	AQ
Sedana Medical files submission for paediatric indication	12-20	AQ
Sedana Medical secures data exclusivity and market protection for Sedaconda[®] (isoflurane) until 2031	11-22	AQ
Key results of Sedana Medical's paediatric study IsoCOMFORT published	11-16	AQ
Sedana Medical Q3 - Accelerated geographical expansion up next	23-10-30	AQ
Sedana Medical AB's Interim report January-September 2023	23-10-26	AQ
Sedana Medical's Nomination Committee established	23-10-24	AQ
The SESAR investigator-initiated trial completes patient enrollment	23-10-23	AQ
Sedana Medical receives market approval in the UK	23-10-10	AQ
Invitation to presentation of Sedana Medical's interim report for the third quarter 2023	23-10-05	AQ

No results for this search